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Abstract
Objective—We sought to examine the risk of mortality associated with nonobstructive coronary 
artery disease (CAD) and to determine the impact of baseline statin and aspirin use on mortality.
Approach and Results—Coronary computed tomographic angiography permits direct 
visualization of nonobstructive CAD. To date, the prognostic implications of nonobstructive CAD 
and the potential benefit of directing therapy based on nonobstructive CAD have not been 
carefully examined. A total of 27 125 consecutive patients who underwent computed tomographic 
angiography (12 enrolling centers and 6 countries) were prospectively entered into the COronary 
CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter (CONFIRM) 
registry. Patients, without history of previous CAD or obstructive CAD, for whom baseline statin 
and aspirin use was available were analyzed. Each coronary segment was classified as normal or 
nonobstructive CAD (1%–49% stenosis). Patients were followed up for a median of 27.2 months 
for all-cause mortality. The study comprised 10 418 patients (5712 normal and 4706 with 
nonobstructive CAD). In multivariable analyses, patients with nonobstructive CAD had a 6% 
(95% confidence interval, 1%–12%) higher risk of mortality for each additional segment with 
nonobstructive plaque (P=0.021). Baseline statin use was associated with a reduced risk of 
mortality (hazard ratio, 0.44; 95% confidence interval, 0.28–0.68; P=0.0003), a benefit that was 
present for individuals with nonobstructive CAD (hazard ratio, 0.32; 95% confidence interval, 
0.19–0.55; P<0.001) but not for those without plaque (hazard ratio, 0.66; 95% confidence interval, 
0.30–1.43; P=0.287). When stratified by National Cholesterol Education Program/Adult 
Treatment Program III, no mortality benefit was observed in individuals without plaque. Aspirin 
use was not associated with mortality benefit, irrespective of the status of plaque.
Conclusions—The presence and extent of nonobstructive CAD predicted mortality. Baseline 
statin therapy was associated with a significant reduction in mortality for individuals with 
nonobstructive CAD but not for individuals without CAD.
Clinical Trial Registration—URL: http://clinicaltrials.gov/. Unique identifier NCT01443637
Keywords
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Coronary computed tomographic angiography (CTA) is a noninvasive angiographic 
modality that allows for direct visualization of obstructive and nonobstructive coronary 
artery disease (CAD).1–7 Although several previous studies have carefully examined the 
prognostic implications of obstructive CAD for individuals undergoing coronary CTA, the 
relationship of nonobstructive CAD to future adverse events remains not completely 
understood.
Furthermore, the decisions on primary prevention for individuals with nonobstructive CAD 
remain unclear. Statin and aspirin treatment, for primary prevention, is recommended for 
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patients at high risk of future cardiovascular events based on clinical or laboratory markers, 
such as those with diabetes mellitus, dyslipidemia, high Framingham or National 
Cholesterol Education Program/Adult Treatment Program III (NCEP/ATP III) risk scores, or 
intermediate Framingham Risk Score with elevated high-sensitivity-C-reactive protein.8,9 
Several recent analyses have directly challenged the efficacy of statin or aspirin therapy in 
primary prevention.10–12 Whether the use of coronary CTA to identify nonobstructive CAD 
offers a feasible method by which at-risk patients can be identified and effectively treated 
remains unknown.
Therefore, using a large prospective multicenter international registry, we examined the risk 
of mortality and the impact of baseline statin and aspirin use on mortality risk in individuals 
without obstructive CAD by coronary CTA.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Study Population
Of the 27 125 CONFIRM registry patients, centers without medication data were excluded 
(3 centers with 7422 patients). An additional 6074 patients were excluded for incomplete 
coronary plaque information (836 patients), history of myocardial infarction or 
revascularization (1491 patients), congenital heart disease (119 patients), missing body mass 
index (449 patients), missing age (2 patient), and obstructive CAD diagnosed on coronary 
CTA (3162 patients). Of the remaining 13 629 patients, 3211 (23.6%) patients had missing 
statin or aspirin information. For those with numeric values of lipoproteins, total cholesterol 
was 191±43 mg/dL (n=7426), low-density lipoprotein cholesterol was 117.2±36.1 mg/dL 
(n=6831), and high-density lipo-protein cholesterol was 53.4±16.3 mg/dL (n=7263).
Follow-up (median, 27.2 [interquartile range, 17.7–40.8] months) was available for 99.3% 
of patients. Although few were lost to follow-up (77 [0.7%] patients), patients lost to follow-
up were younger (48.7±11.5 years) and were less likely to be hypertensive (31.2%) or 
dyslipidemic (40.3%; P<0.01 for all).
A total of 10 418 patients (5712 with normal coronary arteries and 4706 with nonobstructive 
CAD) met the enrolment criteria and were analyzed (Table 1). There were observed 
differences between statin and nonstatin users for age (60.5 versus 55.6 years; P<0.001), and 
prevalence of hypertension (54.7% versus 42.3%; P<0.001), diabetes mellitus (18.5% versus 
8.4%; P<0.001), dyslipidemia (85.0% versus 39.1%, P<0.001), but not smoking (24.7% 
versus 25.5%; P=0.38). Important also clinical differences existed between aspirin users and 
nonaspirin users for measures of age (59.6 versus 55.8 years; P<0.001), hypertension 
(54.5% versus 51.6%; P<0.001), diabetes mellitus (15.5% versus 9.5%; P<0.001), 
dyslipidemia (62.3% versus 49.5%; P<0.001), but not smoking (25.0% versus 25.4%; 
P=0.67).
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Compared with patients with normal coronary arteries, those with nonobstructive CAD were 
older, more often men, had more cardiac risk factors, and had higher NCEP/ATP III risk 
scores (P<0.001 for all). Patients with nonobstructive CAD by coronary CTA were more 
likely to be taking statins (43.2% versus 25.1%; P<0.001) and aspirin (46.2% versus 30.8%; 
P<0.001) at the time of coronary CTA when compared with patients without CAD by 
coronary CTA.
At follow-up, there were a total of 120 deaths. Seventy-nine deaths occurred in 4706 
patients with nonobstructive coronary plaque (1.68%) and 41 deaths occurred in the 5712 
individuals with normal coronary arteries (0.72%). Of the 3465 patients treated with statins, 
there were a total of 29 (0.76%) deaths, whereas of the 6953 patients without statin therapy, 
there were 91 (1.31%) deaths. The relationship of statin use and plaque as a function of 
mortality exhibited differences. Deaths occurred in 9 (0.6%) statin-using patients compared 
with 32 (0.8%) non–statin-using patients (P=0.64) with normal coronary arteries, whereas 
occurring in 20 (1.0%) statin-using patients and 59 (2.2%) non–statin-using patients 
(P=0.001) with nonobstructive CAD.
Univariable Analysis of Clinical Variables and Medications for All-Cause Mortality
In univariable analysis of the entire study cohort, age, cardiac risk factors, and NCEP/ATP 
III risk were associated with all-cause mortality (Table 2). Baseline statin therapy was 
associated with lower mortality in the entire study cohort (hazard ratio [HR], 0.65 [0.43–
0.99]; P=0.046) and those with nonobstructive CAD (HR, 0.45 [0.27–0.75]; P=0.002), but 
not in patients with normal coronary arteries (HR, 0.84 [0.40–1.76]; P=0.646). Aspirin use 
at baseline was not associated with differences in survival in the overall study group (HR, 
0.89 [0.61–1.3]; P=0.537) or in those with and without nonobstructive CAD (HR, 0.72 
[0.46–1.14]; P=0.161) and (HR, 0.84 [0.40–1.76]; P=0.646, respectively).
Nonobstructive CAD and All-Cause Mortality
When compared with individuals with normal coronary arteries, patients with 
nonobstructive CAD in Coronary computed tomographic angiography (CCTA) experienced 
higher mortality and there was incremental risk both with the number of coronary vessels 
and the number of coronary segments involved (Table 3; Figure 1). The relationship 
between the summed total number of segments with nonobstructive CAD and mortality risk 
was assessed. All segment scores >0 were associated with increased mortality risk, and there 
was no lower threshold for the absence of mortality risk.
Statin and Aspirin Primary Prevention and All-Cause Mortality
Statin use at the time of CCTA was associated with lower mortality (0.76% versus 1.31%) 
and a lower annual death rate (0.33% versus 0.59%; P=0.032). In patients with 
nonobstructive CAD, the annual death rate was significantly lower in those (0.47% and 
1.04%; P=0.002). Conversely, aspirin therapy was not (1.04% versus 1.22%; P=0.473) 
associated with an improvement in all-cause mortality. In multivariable risk-adjusted 
models, statin use was associated with a significant survival benefit (HR, 0.52; 95% 
confidence interval, 0.34–0.79; P=0.002); however, an interaction analysis between statin 
use and nonobstructive CAD showed the survival benefit of statin use without an obvious 
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difference between those with plaque and those with normal coronary arteries (P=0.233). 
Further subgroup analysis showed that the effect of statin use was only observed for patients 
with nonobstructive CAD (HR, 0.39 [0.23–0.65]; P<0.001) and was not observed in patients 
with normal coronary arteries (HR, 0.64 [0.30–1.37]; P=0.252; Table 4). The lower HR for 
patients with nonobstructive CAD suggests that a larger study will be needed to identify an 
interaction (Figures 2 and 3).
When stratified by NCEP/ATP III risk, the beneficial effect of statins was observed in 
patients with nonobstructive CAD and in a subanalysis of these patients, a significant 
reduction in mortality was observed in those patients with coronary atherosclerosis and at 
intermediate NCEP/ATP III risk. A trend was observed in patients at high NCEP/ATP III 
risk (P=0.060; Table 5). Further subgroup analyses in the univariable models and also 
multivariable models adjusting for NCEP/ATP III risk, both showed that mortality reduction 
was also observed across many subgroups taking statins at baseline (Figure 4). Particularly, 
there was a significant interaction between hypertension and statins (P=0.013) with statins 
therapy being more effective in hypertensive patients versus normotensive patients (HR, 
0.35 [0.20–0.60] versus 1.13 [0.56–2.30]) There was also weak interaction between diabetes 
mellitus and statin use (P=0.051) such that patients with diabetes mellitus seemed to have a 
greater benefit from statin therapy. Initial analysis of suggested a trend toward benefit of 
statin therapy in patients without dyslipidemia. Acknowledging that diabetics could be 
categorized as without dyslipidemia, a post hoc analysis was performed excluding diabetics. 
The HR for patients with dyslipidemia was 0.70 (0.28–1.77) and without dyslipidemia was 
1.09 (0.55–2.15).
Discussion
The present study represents the first large prospective multicenter international study to 
estimate the risk of mortality for patients with nonobstructive CAD, and further determine 
the therapeutic implications of statin and aspirin use in patients with nonobstructive CAD, 
stratified by NCEP/ATP III risk. In this intermediate-term follow-up, we identified a 
relationship between increasing burden of nonobstructive CAD and higher mortality rates 
and observed a reduction in mortality risk associated with baseline statin therapy but not 
aspirin, a finding that may be because of a statistical underpowering because of the number 
of observed events (n=120). This finding was accentuated for individuals with coronary 
CTA-identified nonobstructive CAD and intermediate NCEP/ATP III risk. Although 
underpowered, a trend was observed in those patients with high NCEP/ATP III risk and 
nonobstructive CAD. Importantly, we observed no significant mortality benefit of statins at 
baseline in those with normal coronary arteries by coronary CTA.
These findings in patients with nonobstructive CAD, extend those of previous studies that 
have focused primarily on the presence, extent, and severity of obstructive CAD,2,13,14 but 
confirm those recently observed with invasive coronary angiography.15 Because of the size 
of our cohort, we were able to examine the hazards of nonobstructive CAD as stratified by 
NCEP/ATP III risk, and observed a low mortality risk, over the follow-up period, of patients 
with nonobstructive CAD already considered low risk by clinical risk assessment. As well, 
during this follow-up period, we identified no mortality benefit associated with statin use in 
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patients who were considered higher clinical risk but without evidence of coronary CTA-
identified plaque.
Although it remains possible that some of the nonobstructive lesions (1%–49% diameter 
stenosis) could result in lesion-specific ischemia, it is likely that these were few in 
number,16 and more likely to be undetectable using traditional methods of CAD evaluation, 
such as exercise treadmill testing, stress echocardiography, and myocardial perfusion 
imaging. Previous investigations have shown that minor coronary stenoses are associated the 
majority of acute myocardial infarctions and sudden cardiac deaths. Thus, our analysis 
highlights a potential advantage of atherosclerosis imaging with coronary CTA and its 
potential to direct patient therapy.
In this regard, the present study findings also sought to examine the benefit of medical 
therapy for reduction of mortality in individuals with nonobstructive CAD. Although statin 
therapy is routinely advocated and prescribed for patients with documented cardiovascular 
disease,17–28 the evidence underlying the efficacy in primary prevention is less 
robust.10,11,29–32 The Cochrane meta-analysis and a meta-analysis by Kostis et al 
demonstrated a reduction in total mortality with statin use, whereas a meta-analysis by Ray 
et al11 showed a strong trend toward benefit but the confidence interval overlapped 
1.0.10,32,33 The results of our study further lend support for statin use in primary prevention, 
specifically in those with subclinical atherosclerosis.
Similarly, the benefit of aspirin therapy for primary prevention has also been questioned.12 
At present, statin and aspirin treatment recommendations for primary prevention exist only 
for patients at high risk of future cardiovascular events. To date, these high-risk 
classifications have been restricted to definitions based on clinical or laboratory markers, 
and include diabetes mellitus, dyslipidemia, high Framingham or NCEP/ATP III risk scores, 
or intermediate Framingham Risk Score with elevated high-sensitivity C-reactive protein.8,9 
At present, no uniform recommendation exists for primary prevention therapies based on 
imaging findings, and results of the present study challenge these recommendations, and 
suggest that the individual with intermediate or high NCEP/ATP III risk and nonobstructive 
CAD may derive significant benefit from statin therapy.
Attractive to clinicians and healthcare payers is the potential shift of primary prevention 
treatment from a population-based treat all patients paradigm to one of individualized 
tailoring of therapies to those who actually have disease and are actually at risk for incident 
adverse events. Our study results identified higher risk for patients who had both elevated 
clinical risk scores and nonobstructive CAD, with no increased risk in individuals who had 
either one or the other alone. Although it is currently unknown whether statin therapy in 
patients with subclinical atherosclerosis improves outcomes, the current study results 
suggest that statin therapy in patients with nonobstructive plaque may be of mortality 
benefit. Given several recent analyses that have failed to show efficacy of statin or aspirin 
therapy for primary prevention,10–12 proof that coronary CTA identifies patients who benefit 
from prevention strategies will require extensive corroboration in longer term follow-up 
studies and with additional nonfatal and fatal cardiovascular end points. In a collaborative 
meta-analysis of 6 primary prevention trials (95 000 patients), no apparent mortality benefit 
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was observed with aspirin therapy.12 As such, current guidelines do not recommend aspirin 
to prevent ischemic vascular events in patients without evidence of manifest vascular 
disease.29 In daily coronary CTA practice, the identification of patients with nonobstructive 
CAD is common. Whether the presence of nonobstructive CAD by coronary CTA 
constitutes manifest vascular disease has remained a clinical challenge, and many clinicians 
have adopted a protocol of reflexive statin or aspirin use for these patients. However, the use 
of aspirin was not significantly associated with mortality reduction in our patient cohort, 
even if coronary atherosclerotic plaque was present. Given the wide confidence intervals 
associated with aspirin use, caution should be taken when interpreting these results. The HR 
ratios (0.64 and 0.75) associated with aspirin use may be clinically important but were not 
statistically significant in our study, which may be a function of power. Additional study is 
needed before definitive conclusions on aspirin therapy can be made.
Limitations
This study is not without limitations. We included information on statin use at baseline; 
however, 23% of patients did not have medication information, which could result in a bias 
in our population. As well, we do not have data on the initial statin dose, subsequent 
initiation, discontinuation, dose modification, or compliance changes that may have 
occurred after coronary CTA. Although longitudinal differences in statin use may 
significantly affect study outcomes, we think that patients already being treated with statins 
would have been less likely to discontinue therapy after documentation of nonobstructive 
CAD.30–32 Indeed, the initiation of statins after coronary CTA in individuals with 
nonobstructive CAD would serve to reduce the apparent difference in outcomes between the 
statin and no-statin groups and would have resulted in the underestimation rather than 
overestimation of the true benefit of statin therapy. Conversely patients with normal arteries 
may have discontinued statin therapy, thereby underestimating the benefit of statins in this 
subpopulation. Although a recommendation cannot be made on discontinuing statin therapy 
in those without coronary atherosclerosis on CCTA, Blaha et al33 have previously 
demonstrated that the absence of coronary calcification in the asymptomatic population 
portended an excellent prognosis with a 10-year mortality rate of ≈1%. Similarly, there is 
also a lack of data on pretherapy lipid profiles and subsequent changes in lipid profile, 
which could also affect our conclusions. Additional large-scale studies examining the impact 
of statin therapy on outcomes in individuals with nonobstructive CAD by CCTA now seem 
warranted. Finally, it is possible that the higher use of statins may be explained by factors 
beyond the scope of this study, such as better access to healthcare or healthier lifestyles.
We used all-cause mortality as the primary end point for our study, given its unparalleled 
clinical importance and freedom from ascertainment bias. However, as specific causes of 
death for each patient were not uniformly available at all sites, the true proportion of deaths 
that may have been attributable to cardiovascular events in the study population is unknown. 
Also germane to this limitation is that the NCEP/ATP III risk algorithms are aimed at 
prediction of future cardiovascular events and not all-cause mortality. Consequently, the 
present study may result in the underestimation of the prognostic power of clinical variables 
and overestimate those of coronary CTA and statin therapy. Although the capture of other 
major adverse cardiovascular events (eg, stroke) is desirable, one distinct advantage of using 
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all-cause mortality as a primary outcome measure is its ability to capture adverse deaths that 
may have been related to medication use (eg, hemorrhagic stroke, liver failure, and 
rhabdomyolysis).
This study is comprised a cohort of individuals who were clinically referred for coronary 
CTA for suspected CAD, with the majority being symptomatic. Although our cohort’s 
symptoms are unlikely to be related to nonobstructive plaque, the generalized application of 
our study findings to asymptomatic individuals remains uncertain.
Conclusions
In this intermediate-term follow-up of individuals undergoing CCTA, the presence and 
extent of nonobstructive CAD are associated with increased mortality. Baseline statin 
therapy seems to be associated with a significant reduction in mortality for individuals with 
nonobstructive CAD. Future studies applying targeted therapies to patients with 
nonobstructive CAD should be considered. Whether statin therapy benefits those with 
normal coronary arteries remains uncertain and requires further investigation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
This study was to examine a large-scale population of patients with nonobstructive 
coronary artery disease—as diagnosed by coronary computed tomographic angiography
—and to examine the prognosis of these findings in relation to treatment with statins and 
aspirin. This study found that statins, but not aspirin, was highly efficacious at reducing 
the rates of death for patients with nonobstructive plaque.
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Figure 1. 
Kaplan–Meier Survival curves as a function of number of major coronary arteries with 
nonobstructive coronary artery disease (CAD; 0 [blue line], 1 [green line], 2 [red line], and 3 
[light blue line] vessels with coronary atherosclerosis).
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Figure 2. 
Kaplan–Meier survival curves as a function of statin use in patients without coronary 
plaque.
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Figure 3. 
Kaplan–Meier survival curves as a function of statin use in patients with coronary plaque.
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Figure 4. 
Forest plot of subgroup analyses, adjusted for National Cholesterol Education Program/
Adult Treatment Program III Risk. BMI indicates body mass index; CAD, coronary artery 
disease; and CI, confidence interval.
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Table 1
Patient Characteristics
All Patients
n=10418
No Plaque
n=5712
Nonobstructive CAD
n=4706 P Value*
Age, y 57.2±11.8 53.7±11.8 61.6±10.3 <0.001
Men 5490 (52.7%) 2630 (46.0%) 2860 (60.8%) <0.001
Body mass index, kg/m2 26.7±5.1 26.4±5.1 27.0±5.1 <0.001
Cardiac risk factors
 Smoker/ex-smoker 2626 (25.2%) 1248 (21.8%) 1378 (29.3%) <0.001
 Hypertension 4837 (46.4%) 2444 (42.8%) 2393 (50.8%) <0.001
 Dyslipidemia† 5662 (54.3%) 2888 (50.6%) 2774 (58.9%) <0.001
 Diabetes mellitus 1226 (11.8%) 525 (9.2%)   701 (14.9%) <0.001
 Family history of CAD 2885 (27.7%) 1501 (26.3%)  1384 (29.4%) <0.001
Indications for study
 Chest pain 6012 (57.7%) 3566 (62.4%)  2446 (52.0%) <0.001
 Typical angina 1094 (10.5%)   625 (10.9%)    469 (10.0%)   0.109
 Dyspnea 784 (7.5%) 358 (6.3%)  426 (9.1%) <0.001
 Chest pain+dyspnea 1127 (10.8%)   586 (10.3%)    541 (11.5%)   0.043
NCEP/ATP III risk
 Low risk 3240 (31.1%) 2155 (37.7%)  1085 (23.1%) <0.001
 Intermediate risk 5699 (54.7%) 2899 (50.8%)  2800 (59.5%) <0.001
 High risk 1479 (14.2%)   658 (11.5%)    821 (17.4%) <0.001
Medications
 Aspirin 3932 (37.7%) 1758 (30.8%)  2174 (46.2%) <0.001
 Statin 3465 (33.3%) 1432 (25.1%)  2033 (43.2%) <0.001
Values are given as mean±SD or n (%). CAD indicates coronary artery disease; and NCEP/ATP III, National Cholesterol Education Program/Adult 
Treatment Program III.
*Comparison of patients with no plaque and with nonobstructive CAD.
†Self-reported dyslipidemia.
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Table 4
Cox Models for All-Cause Mortality in Patients With Nonobstructive CAD
Models Hazard Ratio* (95% CI) P Value
All patients (n=10 418)
 Statin therapy 0.52 (0.34–0.79) 0.002
 ASA therapy 0.77 (0.53–1.12) 0.173
Nonobstructive CAD (n=4706)
 Statin therapy 0.39 (0.23–0.65) <0.001  
 ASA therapy 0.66 (0.42–1.04) 0.070
No coronary plaque (n=5712)
 Statin therapy 0.64 (0.30–1.37) 0.252
 ASA therapy 0.73 (0.37–1.47) 0.384
CAD indicates coronary artery disease; and CI, confidence interval.
*Adjusted for National Cholesterol Education Program/Adult Treatment Program III risk.
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Table 5
Multivariable Hazard Ratios for All-Cause Mortality of Individuals Treated at Baseline With Statins as 
Stratified by NCEP/ATP III Risk
HR 95% CI P Value
Overall study group
 NCEP/ATP III risk
  Low risk 2.52 0.98–6.51   0.056
  Intermediate risk 0.39 0.21–0.72   0.003
  High risk 0.40 0.19–0.84   0.015
Normal
 NCEP/ATP III risk
  Low risk 2.55 0.64–10.22   0.637
  Intermediate risk 0.69 0.23–2.07   0.503
  High risk 0.25 0.06–1.11   0.068
Nonobstructive
 NCEP/ATP III risk
  Low risk 2.07 0.55–7.72   0.281
  Intermediate risk 0.24 0.11–0.52 <0.001
  High risk 0.45 0.19–1.06   0.068
CI indicates confidence interval; HR, hazard ratio; and NCEP/ATP III, National Cholesterol Education Program/Adult Treatment Program III.
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